Hong Kong-Listed Biotech and Pharma Stocks Rally Early in Session, Wuxi Apptec Surpasses HK$200 Milestone to Hit Record High

Deep News

Aug 10

Hong Kong-listed biotech and pharmaceutical stocks posted strong gains at the start of the trading session.

Wuxi Apptec (HKEx: 02359) surged more than 5% at one point, with its share price breaking through the HK$200 mark to set a new all-time high. The stock is currently up over 4%. Meanwhile, Zai Lab (HKEx: 9688) advanced more than 5%, while InnoCare Pharma (HKEx: 9969) and WuXi Biologics (HKEx: 2269) each gained over 3%.

In a research report, Orient Securities recommended that investors focus on two key growth opportunities in the weight-loss metabolic space: oral semaglutide and the Foundayo platform. The brokerage also noted that Wuxi Apptec's small-molecule D&M (development and manufacturing) segment is experiencing accelerated growth on a large base, signaling that the domestic small-molecule CDMO sector is poised to enter a new growth cycle over the next three to five years. This trend is expected to gradually accelerate order intake and revenue recognition for related companies, with profit growth potentially exceeding expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1111759926"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111759926\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111759926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111759926","market":"other","top_or_hot":-1,"title":"Hong Kong-Listed Biotech and Pharma Stocks Rally Early in Session, Wuxi Apptec Surpasses HK$200 Milestone to Hit Record High","media":"Deep News","content":"<p>Hong Kong-listed biotech and pharmaceutical stocks posted strong gains at the start of the trading session.<br><br><b>Wuxi Apptec</b> (HKEx: 02359) surged more than 5% at one point, with its share price breaking through the HK$200 mark to set a new all-time high. The stock is currently up over 4%. Meanwhile, <b>Zai Lab</b> (HKEx: 9688) advanced more than 5%, while <b>InnoCare Pharma</b> (HKEx: 9969) and <b>WuXi Biologics</b> (HKEx: 2269) each gained over 3%.<br><br>In a research report, <b>Orient Securities</b> recommended that investors focus on two key growth opportunities in the weight-loss metabolic space: oral semaglutide and the Foundayo platform. The brokerage also noted that <b>Wuxi Apptec</b>'s small-molecule D&M (development and manufacturing) segment is experiencing accelerated growth on a large base, signaling that the domestic small-molecule CDMO sector is poised to enter a new growth cycle over the next three to five years. This trend is expected to gradually accelerate order intake and revenue recognition for related companies, with profit growth potentially exceeding expectations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong-Listed Biotech and Pharma Stocks Rally Early in Session, Wuxi Apptec Surpasses HK$200 Milestone to Hit Record High</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong-Listed Biotech and Pharma Stocks Rally Early in Session, Wuxi Apptec Surpasses HK$200 Milestone to Hit Record High\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-10 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed biotech and pharmaceutical stocks posted strong gains at the start of the trading session.<br><br><b>Wuxi Apptec</b> (HKEx: 02359) surged more than 5% at one point, with its share price breaking through the HK$200 mark to set a new all-time high. The stock is currently up over 4%. Meanwhile, <b>Zai Lab</b> (HKEx: 9688) advanced more than 5%, while <b>InnoCare Pharma</b> (HKEx: 9969) and <b>WuXi Biologics</b> (HKEx: 2269) each gained over 3%.<br><br>In a research report, <b>Orient Securities</b> recommended that investors focus on two key growth opportunities in the weight-loss metabolic space: oral semaglutide and the Foundayo platform. The brokerage also noted that <b>Wuxi Apptec</b>'s small-molecule D&M (development and manufacturing) segment is experiencing accelerated growth on a large base, signaling that the domestic small-molecule CDMO sector is poised to enter a new growth cycle over the next three to five years. This trend is expected to gradually accelerate order intake and revenue recognition for related companies, with profit growth potentially exceeding expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"399441","symbol_name":"生物医药","start_time":0,"source_url":"","article_id":"1111759926","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111759926","pubTimestamp":1786326618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Hong Kong-listed biotech and pharmaceutical stocks posted strong gains at the start of the trading session.Wuxi Apptec (HKEx: 02359) surged more than 5% at one point, with its share price breaking...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","399441":"生物医药","603259":"药明康德","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","02359":"药明康德","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK1576":"医药外包概念","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK4581":"高盛持仓","LU0700851271.USD":"NINETY ONE GSF EMERGING MARKETS MULTI-ASSET \"A\" (USD) ACC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0611395673.USD":"NINETY ONE GSF EMERGING MARKETS EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","XBI":"SPDR S&P Biotech ETF","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK1583":"高瓴概念","BK0216":"研究试验","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","BK4585":"ETF&股票定投概念","EWH":"香港ETF-iShares MSCI","VXUS":"国际股票ETF-Vanguard","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","KCAI":"KraneShares China Alpha Index ETF","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1141":"生命科学工具和服务"},"translate_title":"香港上市生物科技和医药股早盘反弹，药明康德突破200港元里程碑创历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"603259":1,"EWH":1,"KCAI":1,"VXUS":1,"XBI":1,"02359":1},"content_text":"Hong Kong-listed biotech and pharmaceutical stocks posted strong gains at the start of the trading session.Wuxi Apptec (HKEx: 02359) surged more than 5% at one point, with its share price breaking through the HK$200 mark to set a new all-time high. The stock is currently up over 4%. Meanwhile, Zai Lab (HKEx: 9688) advanced more than 5%, while InnoCare Pharma (HKEx: 9969) and WuXi Biologics (HKEx: 2269) each gained over 3%.In a research report, Orient Securities recommended that investors focus on two key growth opportunities in the weight-loss metabolic space: oral semaglutide and the Foundayo platform. The brokerage also noted that Wuxi Apptec's small-molecule D&M (development and manufacturing) segment is experiencing accelerated growth on a large base, signaling that the domestic small-molecule CDMO sector is poised to enter a new growth cycle over the next three to five years. This trend is expected to gradually accelerate order intake and revenue recognition for related companies, with profit growth potentially exceeding expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}